News Archive

News Archive

Immune master regulator orchestrates responses to parasite infection

Immune master regulator orchestrates response to parasite infection. Image credit: Dave Goulding, Wellcome Sanger Institute

Immune master regulator orchestrates responses to parasite infection

Receptor IL-10R is vital to coordinating the body's immune response to whipworms, preventing uncontrolled infection and gut lining damage

Researchers from the Wellcome Sanger Institute and collaborators have revealed that the interleukin 10 receptor (IL-10R) is critical to prevent uncontrolled whipworm infection in mice and a damaging immune response in the gut.

GARFIELD classifies disease-relevant changes in the genome

ibdzoomhome.png

GARFIELD classifies disease-relevant changes in the genome

New approach reveals role of genomic changes in a disease, both within and outside genes

Researchers at the Wellcome Sanger Institute and EMBL’s European Bioinformatics Institute (EMBL-EBI) have developed a new approach to understand the functional effects of genetic variations associated with a disease, even if they aren't located in a gene. Using this approach could help scientists uncover previously unknown mechanisms that control gene activity and determine whether or not cell work normally or, in the case of genetic diseases, the cells malfunction.

Huge step forward in decoding genomes of small species

Sanger Institute researchers, working with PacBio, have obtained a high-quality whole genome from just a single mosquito's DNA

Huge step forward in decoding genomes of small species

Scientists from the Wellcome Sanger Institute and Pacific Biosciences use just ‘half a mosquito-worth’ of DNA to produce a whole, high quality, single mosquito's genome

The team were able to generate a high quality genome from just 100 nanograms of DNA. This advance could have positive potential for humans as well, for example in the future it could be possible to assemble the whole genetic code of a patient’s cancer, from a single biopsy.

Ian Dunham appointed as Open Targets Director

Ian Dunham has been appointed Director of Open Targets

Ian Dunham appointed as Open Targets Director

Open Targets is the public-private partnership on the Wellcome Genome Campus that aims to transform drug discovery through the systematic identification and prioritisation of targets

Ian Dunham will focus on the delivery of Open Targets’ established research programme to exploit advances in genetics and genomics for drug target identification and prioritisation. He also aims to increase the use of new approaches to the programme, including single-cell sequencing, CRISPR and artificial intelligence.

Genetic study reveals possible new routes to treating osteoarthritis

Genetic study reveals possible new routes to treating osteoarthritis

Genetic study reveals possible new routes to treating osteoarthritis

Scientists discover new genes and biological pathways linked to osteoarthritis, which could help identify starting points for new medicines

Scientists at the Wellcome Sanger Institute, GSK and their collaborators analysed the genomes of over 77,000 people with osteoarthritis. The findings, published in Nature Genetics, revealed new genes and biological pathways linked to the condition, which could help identify starting points for new medicines. It also opportunities for repurposing existing medicines.

CRISPR study reveals new immune system regulators

Th2 cells - new CRISPR study by Sanger Institute reveals new immune system regulators. Image credit: NIAID

CRISPR study reveals new immune system regulators

Map of T cell regulation could aid development of drugs that could activate the immune system

Researchers from the Wellcome Sanger Institute and their collaborators mapped the most important genes for controlling T helper cells, and identified several new potential regulatory genes. Published in Cell, these findings could help scientists develop new treatments to activate the immune system against tumours or infection.

Mystery of Yemen cholera epidemic solved

Cholera_home_dave_goulding.jpg

Mystery of Yemen cholera epidemic solved

Bacteria's genomes reveal that the most likely source of the disease came from Eastern Africa and entered Yemen with the migration of people in and out of the region

Scientists discovered that the cholera strain causing the Yemen epidemic is related to a strain first seen in 2012 in South Asia that has spread globally, but the Yemeni strain did not arrive directly from South Asia or the Middle East. This particular cholera strain was circulating and causing outbreaks in Eastern Africa between 2013 and 2014, prior to appearing in Yemen in 2016.

Statement from GRL Board accepting the findings of the independent investigation into a whistleblowing claim

logo_sanger.png

Statement from GRL Board accepting the findings of the independent investigation into a whistleblowing claim

Genome Research Limited Chair and Director of the Wellcome Sanger Institute outline steps the Institute will put in place to improve its processes

In April 2018 allegations were made against the Sanger Institute Director and other senior members of the Institute in a whistleblowing claim. An independent investigation into the allegations, commissioned by the Board of Directors (the charity’s trustees), was carried out by a barrister, and delivered in October. The allegations were not upheld. The Board of Directors has carefully considered the investigation report and has accepted its findings.

Bird migration and conservation clues in robin and Turtle dove genomes

robinhome2.png

Bird migration and conservation clues in robin and Turtle dove genomes

The genomes were read by the Sanger Institute and its partners, in celebration of Sanger’s 25th anniversary

The genomes, completed today (21 December) will enable researchers to explore the genetic switches controlling bird migration and give insight into the magneto receptors that help robins ‘see’ the Earth’s magnetic fields for navigation. The Turtle dove genome will help conservation efforts to save one of the UK’s fastest declining bird species.

From eye drops to potential leukaemia treatment

Eye drops lead to potential leukaemia treatment

From eye drops to potential leukaemia treatment

Ingredient in pre-clinical treatment for retinal neovascular disease targets gene associated with acute myeloid leukaemia

Sanger Institute researchers and their collaborators discovered that SRPK1 was the target of a compound being developed in eye drops for the treatment of retinal neovascular disease. The team found that the compound strongly inhibited the growth of several MLL-rearranged AML cell lines, but did not inhibit the growth of normal blood stem cells

Pages